» Articles » PMID: 7479629

Lifestyle Intervention: Results of the Treatment of Mild Hypertension Study (TOMHS)

Overview
Journal Prev Med
Specialty Public Health
Date 1995 Jul 1
PMID 7479629
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Questions regarding the efficacy of nonpharmacologic approaches for the treatment of stage 1 hypertension were addressed as part of the Treatment of Mild Hypertension Study (TOMHS), a 4-year, randomized clinical trial (N = 902). This report describes the lifestyle intervention program used in TOMHS, presents data on the lifestyle changes observed, and focuses on the effect of weight loss on blood pressure and blood lipid levels.

Methods: Participants were randomly assigned to receive either placebo or one of five different antihypertensive medications. All took part in a lifestyle intervention program to reduce weight and sodium and alcohol intake and to increase physical activity.

Results: Substantial changes from baseline levels were achieved for all lifestyle intervention variables. Mean weight change was -10.5 lb (-5.6%) at 1 year, -8.5 lb (-4.5%) at 2 years, -7.4 lb (-4.0%) at 3 years, and -5.7 lb (-3.0%) at 4 years. At 4 years, 70% of participants remained below baseline weight and 34% maintained a weight loss of 10 lb or greater. Mean change in urinary sodium excretion was -12.5 mmol/8 hr (-23%) at 1 year, -10.7 mmol/8 hr (-20%) at 2 years, -8.4 mmol/8 hr (-16%) at 3 years, and -4.6 mmol/8 hr (-9%) at 4 years. Alcohol intake declined by 1.6 drinks/week among drinkers at 4 years. Reported leisure physical activity increased by 86% at 1 year and remained 50% above baseline at 4 years. Beneficial changes in blood pressure and serum lipids were associated with these changes.

Conclusions: These results support a role for lifestyle interventions as the initial treatment for stage 1 hypertension and demonstrate that such interventions can be successfully implemented in the clinical setting.

Citing Articles

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S J Atheroscler Thromb. 2023; 31(6):641-853.

PMID: 38123343 PMC: 11150976. DOI: 10.5551/jat.GL2022.


Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.

Castilla-Ojo N, Turkson-Ocran R, Conlin P, Appel L, Miller 3rd E, Juraschek S J Clin Hypertens (Greenwich). 2023; 25(10):915-922.

PMID: 37695134 PMC: 10560966. DOI: 10.1111/jch.14721.


Dietary Habits and Medications to Control Hypertension Among Women of Child-Bearing Age in the United States from 2001 to 2016.

Kovell L, Maxner B, Ayturk D, Moore Simas T, Harrington C, McManus D Am J Hypertens. 2021; 34(9):919-928.

PMID: 33693539 PMC: 8457430. DOI: 10.1093/ajh/hpab041.


Association between obesity, common chronic diseases and health promoting lifestyle profiles in Hong Kong adults: a cross-sectional study.

Leung Y, Lee J, Lai M, Kwok C, Chong K BMC Public Health. 2020; 20(1):1624.

PMID: 33115451 PMC: 7594285. DOI: 10.1186/s12889-020-09726-x.


Factors involved in body weight loss and its maintenance in morbidly obese inpatients.

Tadokoro R, Iida T, Mikura K, Imai H, Murai N, Kaji M Diabetol Int. 2020; 11(1):41-48.

PMID: 31950003 PMC: 6942112. DOI: 10.1007/s13340-019-00403-y.